In the June issue of Contract Pharma, IQVIA Laboratories' Chief Scientific Officer Patrice Hugo discusses the breadth of new tech-enabled analytical laboratory techniques that are making an impact in end-to-end complex drug development. This includes everything from advanced flow cytometry to high-resolution mass spectrometry and in-depth RNA/DNA sequencing.
In this feature article, Dr. Hugo provides the "why" behind the excitement among lab specialists for transformative analytical advances. He also emphasizes the importance of what underpins the use of these solutions to effectively meet the demands of today's clinical trials, including deep expertise, operational consistencies among lab sites for data comparability, therapeutic considerations and more.
Click here to read the full article.